3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 3
2
Phase 2
2
Phase 1/2
2
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Gynecologic
1
Breast
1
Conditions
Breast Neoplasms
27
Melanoma
4
Sarcoma
3
Liposarcoma
3
Ovarian Neoplasms
2
Neoplasms
2
Breast Cancer Metastatic
2
Thymus Neoplasms
1
Teratoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Neoplastic Cells, Circulating
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasm Metastasis
1
Mesothelioma
1
Lymphoma
1
Locoregional Recurrence
1
Liposarcoma, Myxoid
1
Lipoma
1
Leukemia
1
Leiomyosarcoma
1
Hematologic Neoplasms
1
HER2-positive Advanced Breast Cancer
1
HER2 Negative Breast Cancer
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Neoplasms
1
Diffuse Intrinsic Pontine Glioma
1
Interventions
Gemcitabine
53
Bevacizumab
52
Cyclophosphamide
49
Docetaxel
42
Carboplatin
40
pembrolizumab
37
Paclitaxel
36
Fluorouracil
36
Cisplatin
35
Radiotherapy
31
Oxaliplatin
31
Capecitabine
29
Irinotecan
28
Dexamethasone
27
Leucovorin
25
Cetuximab
25
Nivolumab
24
Doxorubicin
22
Drug Therapy
21
Erlotinib Hydrochloride
20
Pemetrexed
19
durvalumab
18
trametinib
17
fludarabine
16
atezolizumab
16
Trastuzumab
16
Sunitinib
16
Rituximab
16
Prednisone
16
Sorafenib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms
×
ribociclib
×
Clear all
NCT02925234
2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2
Recruiting
1,550 enrolled
NCT02187783
2019-07-18
SIGNATURE
Novartis
Phase 2
Completed
106 enrolled
16 charts